Alcohol use and depression: link with adherence and viral suppression in adult patients on antiretroviral therapy in rural Lesotho, Southern Africa: a cross-sectional study

Bernard Cerutti1*, Barbara Broers2, Motlomelo Masetsi3, Olatunbosun Fatunbiyan3, Likabelo Toti-Mokoteli3, Mokete Motlatsi3, Joelle Bader4, Thomas Klimkait5 and Niklaus D Labhardt6

Abstract

Background: Depression and alcohol use disorder have been shown to be associated with poor adherence to antiretroviral therapy (ART). Studies examining their association with viral suppression in rural Africa are, however, scarce.

Methods: This study reports prevalence of depressive symptoms and alcohol use disorder, and their potential association with adherence and viral suppression in adult patients on ART in ten clinics in rural Lesotho, Southern Africa.

Results: Among 1,388 adult patients (69 % women), 80.7 % were alcohol abstinent, 6.3 % were hazardous drinkers (men: 10.7 %, women: 4.4 %, p < 0.001). The prevalence of depressive symptoms was 28.8 % (men 20.2 %, women 32.7 %, p < 0.001). Both alcohol consumption (adjusted odds-ratio: 2.09, 95 % CI: 1.58-2.77) and alcohol use disorder (2.73, 95 % CI: 1.68-4.42) were significantly associated with poor adherence. There was, however, no significant association with viral suppression.

Conclusions: Whereas the results of this study confirm previously reported association of alcohol use disorder with adherence to ART, there was no association with viral suppression.

Trial registration: April 28th 2014; NCT02126696.

Keywords: HIV, antiretroviral therapy, Alcohol, Depression, Medication adherence, Africa

Background

Despite enormous progress in the roll out of HIV prevention and treatment, 2 million new HIV infections and 1.2 million AIDS-related deaths were reported globally in 2014 with Sub-Saharan Africa bearing the highest burden of morbidity and mortality [1].

For many individuals infected with HIV, the scale-up of antiretroviral therapy (ART) has, however, transformed HIV into a chronic disease that does affect their lives, but does not necessarily shorten their life expectancy, as long as continued adherence is maintained [2, 3]. As HIV has turned into a chronic but manageable condition new challenges arise for the patients and health care providers. Good adherence to ART is particularly decisive for biological and clinical outcomes [4, 5]. Evidence-based recommendations for improving adherence include, among many others, targeting patients with substance abuse and mental illness [6]. Several studies report depression as well as alcohol use disorder to be associated with poor adherence to ART in Africa [7–9]. However, most studies look at self-reported or observed adherence, both prone to reporting-bias. Viral suppression is an observer-

*Correspondence: bernard.cerutti@unige.ch
1Faculty of Medicine, University of Geneva, UDREM, 1 Rue Michel Servet, 1211 Geneva 4, Switzerland
Full list of author information is available at the end of the article.

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
independent reflection of drug-adherence and viral load monitoring may be used as an adherence-monitoring tool [10]. Data examining association of depression and alcohol use disorder with viral suppression in Southern Africa are, however, very limited.

Lesotho, an impoverished, landlocked country surrounded by South Africa has the third-highest HIV prevalence in the world [11] and has the highest transmission-rates and the lowest ART-coverage [12] among the hyper-endemic countries in Southern Africa. In this paper we report on prevalence of depressive symptoms and alcohol use, and their potential association with viral suppression in adult patients on ART in rural Lesotho, Southern Africa.

Methods
Study setting and participants
The study Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho (CART-1) is a registered observational study assessing comorbidities and virologic outcomes among patients on first-line ART in Lesotho (registration: April 28th 2014; NCT02126696). Lesotho is a small landlocked country surrounded by South Africa. It has an adult HIV-prevalence of 23.4 % [13] and on-going high transmission rates [12]. Due to severe shortage of medical personnel, HIV/AIDS care is nurse-based in most clinics. The CART-1 study was conducted in two rural districts, Butha-Buthe and Thaba-Tseka. In each district one hospital and four nurse-led health centres were included. All involved facilities receive support through SolidarMed, a Swiss non-for-profit organization that has been assisting the Ministry of Health in the roll out of ART since 2005. During the CART-1 study, all patients on ART ≥ 6 months attending routine follow-up visits between May 5th, 2014 and June 17th, 2014 and willing to participate received viral load measurement and extensive comorbidity screening, including assessment for alcohol use disorder and depressive symptoms. The study-setting has been described elsewhere [14, 15]. Exclusion criteria were being on ART < 6 months, history of treatment interruption ≥ 7 days during the last 3 months, receiving second-line ART.

For the present analysis, patients aged ≥ 16 years with documented viral load, alcohol use disorder and depressive symptoms screening were included.

Measures
Participants were enrolled and screened at their routine ART-visits during the study-period. A trained lay-counsellor collected basic socio-demographic data, assessed adherence and subsequently conducted screening for alcohol use disorder and depressive symptoms. The latter were screened for using the Alcohol use Disorder Identification Test (AUDIT) [16] and the nine-item depression module from the Patient Health Questionnaire (PHQ-9) [17] respectively. Both screening tools have been used in similar settings [7–9]. Interviews were conducted in a separate closed room to ensure confidentiality. The internationally recommended thresholds for “hazardous drinker” (AUDIT-score ≥ 8) “alcohol dependence” (AUDIT-score ≥ 20) and depression (PHQ-9 score ≥ 10) were used, as in other studies in Sub-Saharan Africa [18–21]. AUDIT and PHQ-9 questionnaires were translated by a professional English-Sesotho translator and translated back into English by study-personnel. Meaning of questions after back-translation into English was unchanged. Thereafter, the Sesotho questionnaires were discussed in focus groups involving community workers, health care providers and patients where group members agreed on some minor grammar modification.

After the interviews patients attended their routine ART-consultation and blood for biologic analyses was taken. Routine laboratory exams (full blood count, CD4-cell count, serum gamma-glutamyl transferase, and serum creatinine) were performed at the laboratories of the two hospitals involved in the study, which are both certified national laboratories. Blood for the viral load analyses was collected in a Plasma Preparation Tube (PPT), centrifuged within eight hours and subsequently frozen at - 40°C. PPTs were shipped on dry ice within a maximum of 3 weeks to a reference laboratory in Switzerland. Viral RNA was prepared using an automated extractor (NucliSENS easyMAG, Biomerieux, Switzerland) and quantified using a validated protocol as published [22]. Based on established sensitivity of the protocol, viral suppression was defined as a viral load <80 copies/mL. Adherence was assessed through two different approaches: self-reported adherence using a visual analogue scale (VAS), and pill-count. Low adherence criteria were defined as a VAS-score ≤95 %, or a pill-count <95 %. VAS ≤95 % was associated to virologic failure in a previous study in the same setting [23]. Pill-count ≤95 % has been shown to be associated to lower rates of viral suppression in similar settings [24]. Participants’ wealth index was assessed using the 2009 Lesotho Demographic Health Survey questionnaire [25], which includes the following variables: type of floor, roof, and walls of the house; type of beds, toilet; material used for cooking; access to water; electricity supply; equipment of the household (electricity generator, radio, tv, fix and mobile phone, watch, fridge, bed, computer; access to Internet, bicycle, cart, motorbike, car); owned surface of land; and a complete description of the owned cattle and sheep.

Analysis
Unless specified, mean results and odd ratios (OR) are given with 95 % confidence intervals. Link between dichotomous variables and other covariates were investigated with
generalized linear models with binomial function links, and the different models were compared with chi square test based on the analysis of deviance. For the prevalence or alcohol use, depressive symptoms, self-reported adherence, and viral suppression, difference between gender were adjusted by age and wealth index. For virologic suppression, the link with the following covariates were investigated: age, sex, wealth index, type of health facility (health centre or hospital), nucleosid reverse transcriptase inhibitor (NRTI) and non-nucleosid-reverse transcriptase inhibitor (NNRTI) of the current ART-regimen, PHQ score, AUDIT score, and self-reported adherence (VAS and pill count). The wealth-index was generated through principal component analysis [26]. Links between two categorical variables were investigated with Chi-squared test. All analyses were run on R 2.15.3 (the R Foundation for Statistical Computing), and TIBCO Spotfire S + * 8.1 for Windows (TIBCO Software Inc).

Results

A total of 1,811 adult patients attended ART-consultations during the study-period, 213 (11.8 %) were excluded due to pre-specified exclusion criteria (138 on ART < 6 months, 50 refused participation, 25 on second-line ART) and 35 (1.9 %) due to missing viral load data. Among the 1,563 patients, 1,388 (88.8 %) had both, documented PHQ-9 and AUDIT scores. Main results, stratified by sex, are summarized in Table 1.

### Alcohol use

The proportion of alcohol abstainers (past 12 months) was 80.7 % (78.6 %-82.8 %; men 68.8 %, 64.4 %-73.2 %; woman 86.0 %, 82.8-88.2 %; \( p < 0.001 \)), and rose from 73.8 % for the lowest quintile of the wealth index to 86.6 % for the highest one (\( p = 0.002 \)). There were 6.3 % of hazardous drinkers (5.1 %-7.6 %; men 10.7 %, 7.7 %-13.6 %; women 4.4 %, 3.1 %-5.7 %, \( p < 0.001 \)), and 0.3 % of dependent drinkers. Among those who drink, the average AUDIT score was 5.92 (5.27-6.56; men 6.16, 5.33-7.00; women 5.67, 4.68-6.66; \( p = 0.454 \)). The level of gamma-glutamyl transferase correlated significantly with the AUDIT score (correlation of the log values: 0.223; \( p < 0.001 \)).

### Depressive symptoms

The average PHQ-9 score was 6.61 (6.31-6.91; men 5.53, 5.01-6.06; women 7.09, 6.73-7.46; \( p < 0.001 \)), and the prevalence of depression (PHQ-9 score \( \geq 10 \)) was 28.8 % (26.4 %-31.2 %; men 20.2 %, 16.4 %-24.0 %; women 32.7 %, 29.7 %-35.6 %; \( p < 0.001 \)). Depression prevalence

### Table 1 Distribution of age, AUDIT and PHQ scores, treatment adherence, and viral suppression

|                          | Overall n = 1,388 | Women n = 958 | Men n = 430 | Odds-ratio* (95 % CI) | \( p \)-value | Adjusted odds-ratio* (95 % CI) | Adjusted \( p \)-value |
|--------------------------|------------------|--------------|------------|-----------------------|--------------|-------------------------------|----------------------|
| Median age (IQR)         | 43.6 (34.5–53.5) | 43.6 (34.5–53.5) | 40.8 (32.4–51.4) | <0.001                |              |                               |                      |
| Alcohol consumption      |                  |              |            |                      |              |                               |                      |
| Yes                      | 268 (19.3 %)     | 134 (14.0 %) | 134 (31.2 %) | 0.35 (0.27-0.47)      | <0.001       | 0.37 (0.28-0.50)              | <0.001               |
| No                       | 1,120 (80.7 %)   | 824 (86.0 %) | 296 (68.8 %) |                       |              |                               |                      |
| Mean AUDIT Score (SD)    |                  |              |            |                      |              |                               |                      |
| among drinkers           | 5.9 (5.4)        | 5.7 (5.8)    | 6.2 (4.9)   | .                     | 0.454        |                               | 0.491                |
| Hazardous consumption    |                  |              |            |                      |              |                               |                      |
| (AUDIT \( \geq 8 \))     | Yes              | 88 (6.3 %)   | 42 (4.4 %)  | 46 (10.7 %)           | 0.38 (0.25-0.59) | <0.001 | 0.39 (0.25-0.60) | <0.001 |
| No                       | 1,300 (93.7 %)   | 916 (95.6 %) | 384 (89.3 %) |                       |              |                               |                      |
| Alcohol dependence       |                  |              |            |                      |              |                               |                      |
| (AUDIT \( \geq 20 \))    | Yes              | 4 (0.3 %)    | 3 (0.3 %)   | 1 (0.2 %)             | .            | .                             | .                    |
| No                       | 1,384 (99.7 %)   | 955 (99.7 %) | 429 (99.8 %) |                       |              |                               |                      |
| Mean PHQ Score (SD)      |                  |              |            |                      |              |                               |                      |
|                             | 6.6 (5.8)        | 7.1 (5.8)    | 5.5 (5.6)   | .                     | <0.001       | .                             | <0.001               |
| Moderate to severe        |                  |              |            |                      |              |                               |                      |
| depression (PHQ-9 \( \geq 10 \)) | Yes              | 400 (28.8 %) | 313 (32.7 %) | 87 (20.2 %)           | 1.89 (1.45-2.49) | <0.001 | 1.92 (1.45-2.54) | <0.001 |
| No                       | 988 (71.2 %)     | 645 (67.3 %) | 343 (79.8 %) |                       |              |                               |                      |
| Mean VAS (SD)             |                  |              |            |                      |              |                               |                      |
|                             | 92.0 (12.2)      | 91.9 (12.3)  | 92.2 (12.0) | .                     | 0.713        |                               | 0.701                |
| Low VAS (\( \leq 95 \% \)) | Yes              | 610 (44.7 %) | 419 (44.6 %) | 191 (45.0 %)          | 0.97 (0.77-1.23) | 0.823 | 0.97 (0.76-1.23) | 0.780 |
| No                       | 754 (55.3 %)     | 521 (55.4 %) | 233 (55.0 %) |                       |              |                               |                      |
| Mean pill count Score (SD)|                  |              |            |                      |              |                               |                      |
|                             | 96.9 (8.3)       | 97.1 (8.1)   | 96.6 (8.6)  | .                     | 0.333        |                               | 0.380                |
| Low pill count (\( \leq 95 \% \)) | Yes              | 301 (22.6 %) | 196 (21.3 %) | 105 (25.5 %)          | 0.79 (0.60-1.04) | 0.093 | 0.81 (0.61-1.08) | 0.148 |
| No                       | 1,029 (77.4 %)   | 723 (78.7 %) | 306 (74.5 %) |                       |              |                               |                      |
| Viral Suppression         |                  |              |            |                      |              |                               |                      |
| (\( \leq 80 \text{ copies/ml} \)) | Yes              | 1,270 (91.5 %) | 883 (92.2 %) | 387 (90.0 %)          | 1.31 (0.88-1.94) | 0.187 | 1.43 (0.96-2.16) | 0.088 |
| No                       | 118 (8.5 %)      | 75 (7.8 %)   | 43 (10.0 %)  |                       |              |                               |                      |

*a the group of reference is the male population  
*b adjusted by age and wealth index
decreased from 33.7 % for the lowest quintile of the wealth index to 20.4 % for the highest one ($p = 0.002$).

There was a significant but weak correlation of 0.09 ($p < 0.001$) between AUDIT and PHQ-9 (men: 0.15, women: 0.10), and no evidence of association between PHQ-9 and the NNRTI (efavirenz versus nevirapine) of the current ART regimen ($p = 0.521$):

### Virologic suppression

The rate of patients who did not achieve virologic suppression was 8.5 % (7.0 %-10.0 %; see Table 2 for further details), with no evidence of difference between sex ($p = 0.158$) or wealth index quintiles ($p = 0.293$). Neither depression (Odds ratio (OR) 1.27; 0.82-1.96), nor any alcohol consumption (OR 0.94; 0.58-1.51), nor hazardous alcohol consumption (OR 0.81; 0.39-1.65), showed significant association with unsuppressed viremia. In a complementary analysis, we applied different cut-off values for VAS and pill count suggested by Denison et al. [27] after ROC curve analysis. We also applied different AUDIT cut-off values for the hazardous consumption of alcohol as sometimes suggested ($\geq 7$ for males, respectively $\geq 6$ for females). In both situations the conclusions remained unchanged.

### Adherence

The median adherence measured with the VAS was 96 % (interquartile range (IQR): 91 %–99 %), with no evidence

### Table 2 Viral suppression and association with socio-demographic characteristics, type of ART-regimen, AUDIT and PHQ scores, and treatment adherence

|                      | Viral load <80 c/mL | $\geq 80$ c/mL | Odds-ratio viral suppression (95 % CI) | p-value |
|----------------------|---------------------|----------------|----------------------------------------|---------|
| **Male**             |                     |                |                                        |         |
| Male                 | 387 (90.0 %)        | 43 (10.0 %)    | 1                                      |         |
| Female               | 883 (92.2 %)        | 75 (7.8 %)     | 1.33 (0.90-2.00)                       | 0.158   |
| Median age (IQR)     |                     |                |                                        |         |
| Age <35 years        | 334 (90.3 %)        | 36 (9.7 %)     | 1                                      |         |
| $\geq$35 years       | 936 (91.9 %)        | 82 (8.1 %)     | 1.23 (0.81-1.86)                       | 0.329   |
| Median wealth index (IQR) | –0.52 (–1.66-1.25) | –0.90 (–1.76-1.13) | 1                                        | 0.180   |
| **Wealth index**     |                     |                |                                        |         |
| Q1b                  | 253 (90.7 %)        | 26 (9.3 %)     | 1                                      | 0.293   |
| Q2                   | 249 (88.9 %)        | 31 (11.1 %)    | 0.83 (0.41-1.64)                       |         |
| Q3                   | 250 (92.6 %)        | 20 (7.4 %)     | 1.28 (0.60-2.75)                       |         |
| Q4                   | 258 (93.8 %)        | 17 (6.2 %)     | 1.56 (0.70-3.46)                       |         |
| Q5                   | 260 (91.5 %)        | 24 (8.5 %)     | 1.11 (0.54-2.31)                       |         |
| **Type of facility** |                     |                |                                        |         |
| Center               | 768 (91.9 %)        | 68 (8.1 %)     | 1                                      | 0.547   |
| Hospital             | 502 (90.9 %)        | 50 (9.1 %)     | 0.89 (0.61-1.30)                       |         |
| **NRTI backbone**    |                     |                |                                        |         |
| AZT/3TCc             | 418 (87.8 %)        | 58 (12.2 %)    | 0.52 (0.34-0.80)                       | 0.004   |
| TDF/3TCd             | 819 (93.3 %)        | 59 (6.7 %)     | 1                                      |         |
| ABC/3Tc              | 13 (92.9 %)         | 1 (7.1 %)      | 0.94 (0.09-9.80)                       |         |
| **NNRTI**            |                     |                |                                        |         |
| EFVg                 | 959 (92.2 %)        | 81 (7.8 %)     | 1                                      | 0.056   |
| NVPh                 | 291 (88.7 %)        | 37 (11.3 %)    | 0.66 (0.44-1.00)                       |         |
| **Median AUDIT Score (IQR)** |                   |                |                                        |         |
| Hazardous consumption| Yes                 | 79 (89.8 %)    | 9 (10.2 %)                             | 0.80 (0.39-1.65) | 0.559   |
| No                  | 1'191 (91.6 %)      | 109 (8.4 %)    | 1                                      |         |
| **Median PHQ-9 Score (IQR)** |                   |                |                                        |         |
| Moderate to severe depression (PHQ-9 $\geq$ 10) | Yes                 | 371 (92.8 %) | 29 (7.3 %)                       | 1.27 (0.82-1.96) | 0.281   |
| No                 | 899 (91.0 %)        | 89 (9.0 %)     | 1                                      |         |
| **VAS (IQR)**        |                     |                |                                        |         |
| Yes                 | 96 (91–99)          | 96 (90–100)    | 1                                      | 0.424a  |
| No                 | 691 (91.6 %)        | 63 (8.4 %)     | 1                                      |         |
| **Low adherence VAS (≤95 %)** |                   |                |                                        |         |
| Yes                 | 558 (91.5 %)        | 52 (8.5 %)     | 1.02 (0.70-1.50)                       | 0.818   |
| No                 | 691 (91.6 %)        | 63 (8.4 %)     | 1                                      |         |
| **Pill count’s tool (IQR)** |                   |                |                                        |         |
| Yes                 | 100 (96–100)        | 100 (96–100)   | 1                                      | 0.851a  |
| No                 | 941 (91.4 %)        | 88 (8.6 %)     | 1                                      |         |

a: Wilcoxon rank-sum test, b: lowest quintile, c: AZT: zidovudine, d: 3TC: lamivudine, e: TDF: tenofovir, f: ABC: abacavir, g: efavirenz, h: nevirapine
of difference between sex ($p = 0.713$). The prevalence of VAS ≤ 95 % was 44.7 % ($p = 0.823$ for difference between sex), decreased from 22.6 % for the lowest quintile of the wealth index to 16.2 % for the highest one ($p < 0.001$), and did not show evidence of association with depressive symptoms ($p = 0.386$). Hazardous alcohol consumption increased the probability of VAS ≤ 95 % (OR 2.89; 1.79-4.66; adjusted by wealth index, type of facility, depressive symptoms: 2.73, 1.68-4.42). For alcohol consumption, these results were 2.19 (1.67-2.90) and 2.09 (1.58-2.77) respectively.

The median adherence measured by pill count was 100 % (IQR 96 %-100 %), with some evidence of lower adherence among men (99 % vs. 100 %; $p = 0.036$). The prevalence of pill count ≤ 95 % was 22.6 % ($p = 0.093$ for difference between sex), and did not show evidence of association with depressive symptoms ($p = 0.725$). Hazardous alcohol consumption increased the probability of low pill count (1.77, 1.08-2.89; adjusted by type of facility and age: 1.68; 1.03-2.75). For alcohol consumption, these results were respectively 1.48 (1.09-2.02) and 1.38 (1.01-1.89).

Discussion

Main findings

This cross-sectional study is among the first reporting on prevalence of depressive symptoms and hazardous alcohol use among adult patients on ART investigating their association with unsuppressed viremia in rural Southern Africa. In line with other studies conducted in similar settings, we found hazardous alcohol use to be associated with low self-reported (VAS) adherence to ART [28, 29] or pill count. In addition we also found association between adherence and alcohol consumption. However, neither hazardous alcohol consumption nor depressive symptoms appeared to be associated with viral suppression through ART.

As an observational cross-sectional facility-based study, interpretation of the results should be limited to patients retained on ART ≥ 6 months. Our study population mainly involved women (69.0 %). This is however representative for the gender-distribution in patients enrolled on ART in Lesotho [15].

Alcohol consumption

Overall alcohol-consumption and rate of hazardous alcohol use were lower than in a recently conducted survey in the general population [28, 29], and are negatively correlated with the wealth index. The significant association between the level of gamma-glutamyl transferase and the AUDIT confirmed the validity of the instrument in this setting. The proportion of alcohol abstainers in our study-population (68.8 % for men, and 86.0 % for women respectively), was similar [30] or higher [31] to the one observed in other studies. Alcohol abstinence was significantly higher than in the general adult population of Lesotho [32] (58.0 % for men and 81.3 % for women). One explanation may be that in general ART-providers at facilities involved advocate for alcohol abstinence when a patient decides starting ART.

The amplitude of the effect of hazardous alcohol consumption on low adherence (adjusted OR 2.72) is higher to the one found in the literature: a meta-analysis published by Hendershot and colleagues in 2009 reported an OR of 1.82 [33]; Denison et al. report a pooled OR of 1.87 [27], and Ayay et al. 2.17 [30]. However, these studies did not examine for association with viral suppression.

Depressive symptoms

In contrast to alcohol consumption, depressive symptoms (31.7 % of women and 20.2 % of men) showed a considerably higher prevalence than the reported 10 % in the general population [34]. There was also a negative association of depressive symptoms with the wealth index. This outcome is similar to the one of the systematic review done by Nakimuli-Mpungu et al. in 2012 [35], with a prevalence of 31.2 %. Our study showed no association of depressive symptoms with viral suppression. This finding is in contrast to the study of Marconi et al. reporting association of depression to unsuppressed viremia in a case–control study [36]. The stronger association between AUDIT- and PHQ-9-score among men in our study suggests that particularly among men alcohol consumption should be addressed in cases where symptoms of depression are found.

Limitations

This study has several limitations: first, it was carried out in two rural districts of Lesotho, and may not be representative of the situation in the whole country – in particular as it does not involve urban areas. Also, whereas the design of CART-1 could reduce bias when compared to a case control study, the hypothesis of biases cannot be ruled out: many variables collected through questionnaires require recall of past events by the participant. Another limitation is the potential of distortion affecting the association between viral suppression and self-reported adherence due the negative cognitive bias in people with depressive symptoms. Moreover, the study involved only patients on ART ≥ 6 months attending routine follow-up visits: prevalence of alcohol use, depressive symptoms, reported adherence is likely to be different among those patients who have been lost to follow-up. Also PHQ-9 and AUDIT were used at the time of enrolment, which did not allow the study of their evolution in time. Finally we were not able to perform multivariate analysis to adjust for confounding when investigating unsuppressed viral load due to the small number of patients with viral load <80 c/mL.

Internationally recommended cut-offs for PHQ-9 and AUDIT were used in this study. PHQ-9 has been used...
to screen HIV-infected persons for depression in several settings in Sub-Saharan Africa [9, 37–40]. Two independent studies, one from Ethiopia and one from Uganda concluded that a score ≥10 was most accurate to diagnose moderate to severe depression [19, 20]. Nevertheless, PHQ-9 and the used cut-off of 10 for diagnosis of depression has never been validated in Lesotho specifically. Similarly, AUDIT and the cut-off of ≥8 and ≥20 for “hazardous alcohol use” and “dependence” in similar settings of neighbouring South Africa [21, 41, 42].

Conclusions

A worth reporting finding in our study is that contrarily to many other publications neither self-reported adherence nor pill-count were associated to viral suppression. Whereas in study settings with well-trained health care providers pill-count and self-reported adherence showed to be predictive for virologic outcomes, they appear to be imprecise in the setting our study was conducted [24, 43]. Similarly Haberer et al. report from a study in Uganda where pill-count and self-reported adherence showed poor correlation to virologic outcomes [44]. With the expected roll-out of viral load technologies in resource-limited settings, routine viral load monitoring – a more objective adherence measurement - may replace traditional adherence measurement in future [10].

In summary, prevalence of depressive symptoms was generally high and increased inversely to household wealth in this population of ART-patients on rural Lesotho, but no association to virologic outcomes could be shown. Prevalence of hazardous alcohol use was lower than in the general population and increased inversely to household wealth. Prevalence among females was very different than among males, underlining the importance of gender-disaggregated data. Hazardous drinking was associated to poor adherence, but not to unsuppressed viral load.

This study underlines the need for integration of mental health care into ART-services. Health care providers should be encouraged to address with their patients alcohol use and depressive symptoms.

Funding

The study was funded by the Swiss Foundation for Excellence and Talent in Biomedical Research through a grant to ND Labhardt. The funder was not involved at any time in the design of the study, collection, analysis, interpretation of data, or writing of the manuscript.

Availability of data and materials

Data are held at the Swiss Tropical and Public Health Institute. Please contact the corresponding author for further information.

Authors’ contributions

NDL was the principal investigator of the study. TK chaired the study. JB was involved in the blood samples analysis and laboratory works. MWA, MMO, OF, LTM, and NDL worked on the patients’ recruitment, following-up, and data collection process. BC, BB, and NDL defined the statistical analysis plan. BC made the statistical analysis and wrote the first draft. All the authors discussed the results, revised the first draft, read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Prior to enrolment patients provided individual oral and written informed consent. A copy of the written consent is available for review by the Editor of this journal.

Ethics approval was received by the National Health Research and Ethics Committee of Lesotho (ID 01–2014) and the “Ethikkommission Nordwest- und Zentralschweiz” (EKZN) in Switzerland (ID 2014–029). Prior to enrolment patients provided individual oral and written informed consent.

Author details

1Faculty of Medicine, University of Geneva, LIDREM, 1 Rue Michel Servet, 1211 Geneva 4, Switzerland. 2Dependences Unit, Department of Community Medicine, Geneva University Hospitals, Geneva, Switzerland. 3SolidarMed, Swiss Organization for Health in Africa, Maseru, Lesotho. 4Department of Biomedicine, University of Basel, Basel, Switzerland. 5Department of Biostatistics, Epidemiology and Public Health Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland. 6Clinical Research Unit, Swiss Tropical and Public Health Institute, Basel, Switzerland.

Received: 24 October 2015 Accepted: 24 June 2016

References

1. UNAIDS. MDG 6: 15 years, 15 lessons of hope from the AIDS response. http://www.unaids.org/en/resources/documents/2015/MDG6_15years-15lessonsfromtheAIDSSresponse. Accessed 8 Mar 2016.
2. Rabkin M, Kruk ME, El-Sadr WM. HIV, aging and continuity care: strengthening health systems to support services for noncommunicable diseases in low-income countries. AIDS Lond Engl. 2012;26 Suppl 1:S75–83.
3. Mutevedzi PC, Newell M-L. Review: The changing face of the HIV epidemic in sub-Saharan Africa. Trop Med Int Health TM IH. 2014;19(10):15–28.
4. Apisarnthanarak A, Mundy LM. Long-term outcomes of HIV-infected patients with <95 % rates of adherence to nonnucleoside reverse-transcriptase inhibitors: Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;51:115–7.
5. Glass TR, Sterne JAC, Schneider M-P, De Geest S, Nicca D, Furrer H, et al. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. AIDS. 2015;29:2195–200.
6. Holtzman CW, Brady KA, Yehia BR. Retention in care and medication adherence: current challenges to antiretroviral therapy success. Drugs. 2015;75:445–54.
7. Sinclair H, Pretorius A, Stein DJ. A counselling line for problem and pathological gambling in South Africa: Preliminary data analysis. J Behav Addict. 2014;3:199–202.
8. Soboka M, Tefaye M, Feyissa GT, Hanlon C. Alcohol use disorders and associated factors among people living with HIV who are attending services in south west Ethiopia. BMC Res Notes. 2014;7:828.

9. Monahan PO, Shacham E, Reece M, Kroenke K, Ong’or OW, Omollo O, et al. Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. J Gen Intern Med. 2009;24:189–97.

10. Bonner K, Meachow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 1999;33:74–8.

11. UNAIDS. Epidemiological Fact Sheet on HIV and AIDS Lesotho. http://www.unaids.org/sites/default/files/epidocuments/LSO.pdf. Accessed 8 Mar 2016.

12. Williams BG, Gouws E, Somse P, Mmesi E, Lwamba C, Chikoko T, et al. Prevalence and predictors, and validation of brief psychiatric rating scales. AIDS Patient Care STDs. 2009;23:615–21.

13. UNAIDS. Developing subnational estimates of HIV prevalence and the number of people living with HIV from survey data. J266SE. 2014. http://www.unaids.org/sites/default/files/media_asset/2014__subnational_estimates_survey_Lesotho_en.pdf. Accessed 8 Mar 2016.

14. Labhardt ND, Bader J, Lejone T, Ringera I, Pfeiffer K, Davies M-A, et al. Is alcohol use disorder associated with higher probability of ART adherence in resource-limited settings? Trop Med Int Health TM IH. 2015;20:914–8.

15. Labhardt ND, Keiser O, Sello M, Lejone T, Pfeiffer K, Davies M-A, et al. Outcomes of antiretroviral treatment programmes in rural Lesotho: health centres and hospitals compared. J Int AIDS Soc. 2013;16:18616.

16. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption—II. Addict Abingdon Engl. 1993;388:791–804.

17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9. J Gen Intern Med. 2001;16:60–17.

18. Seth P, Glaye B, Puech P, De Luca N, et al. AUDIT, AUDIT-C, and AUDIT-D3: Drinking Patterns and Screening for Harmful, Hazardous and Dependent Drinking in Katutura, Namibia. PLoS One. 2015;10:e0120850.

19. Gelaye B, Williams MA, Lemma S, Deyessa N, Berhetebey B, Shibre T, et al. Validity of the patient health questionnaire-9 for depression screening and diagnosis in East Africa. Psychiatry Res. 2013;210:653–61.

20. Akena D, Joska J, Obuku EA, Stein DJ. Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda. AIDS Care. 2013;25:1245–52.

21. Myer L, Smit J, Roux LL, Parker S, Stein DJ, Seedat S. Common mental disorders among HIV-infected individuals in south Africa: Prevalence, predictors, and validation of brief psychiatric rating scales. AIDS Patient Care STDs. 2008;22:147–58.

22. Masimba P, Pituita E, Klimka T, Horvath E, Stoeckle M, Hatz C, et al. Predictors of depression and HIV Type 1 Subtypes in an HIV Type 1 Infected Cohort in Rural Tanzania. AIDS Res Hum Retrovirus. 2013;29:1292–36.

23. Labhardt ND, Lejone T, Setoko M, Poka M, Ehmer J, Pfeiffer K, et al. A clinical prediction score in addition to WHO criteria for antiretroviral treatment failure in resource-limited settings–experience from Lesotho. PLoS One. 2012;7:e47937.

24. Sangeda RZ, Mosh a F, Prosperi M, Aboud S, Verscauteren J, Camacho RJ, et al. Pharmacy refill adherence outperforms self-reported methods in predicting HIV treatment outcome in resource-limited settings. BMC Public Health. 2014;14:1035.

25. Ministry of Health and Social Welfare (MOHSW) Lesotho. ICF Macro. Lesotho Demographic and Health Survey 2009. MOHSW and ICF Macro; 2012. http://www.dhsprogram.com/publications/publication-FR241-DHS-Final-Reports.cfm. Accessed 8 Mar 2016.

26. Howe LD, Galobardes B, Matijasevich A, Gordon D, Johnston D, Onwujekwe O, et al. Measuring socio-economic position for epidemiological studies in low and middle-income countries: a methods of measurement in epidemiology paper. Int J Epidemiol. 2012;41:871–86.

27. Denison JA, Kooi G, Tsai S, Menten J, Torpy K, van Praag E, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS Lond Engl. 2015;29:361–71.

28. WHO. WHO | Stepwise approach to chronic disease risk factor surveillance [Internet]. http://www.who.int/chp/steps/lesotho/en/. Accessed 8 Mar 2016.

29. Siegfried N, Parry CDH, Morojele NK, Watson D. Profile of drinking behaviour and comparison of self-report with the CAGE questionnaire and carbohydrate-deficient transferrin in a rural Lesotho community. Alcohol Alcohol. 2001;36:243–8.

30. Yaya I, Landoth DE, Saka B, Patchell PM, Wasswa P, Abubakari A, et al. Predictors of adherence to antiretroviral therapy among people living with HIV and AIDS at the regional hospital of Sokodé, Togo. BMC Public Health. 2014;14:1308.

31. Kekwaletswe CT, Morojele NK. Alcohol use, antiretroviral therapy adherence, and preferences regarding an alcohol-focused adherence intervention in patients with human immunodeficiency virus. Patient Prefer Adherence. 2014;8:401–13.

32. WHO. WHO | Lesotho [Internet]. http://www.who.int/countries/lso/en/. Accessed 8 Mar 2016.

33. Hendershot CS, Stoner SA, Pantalone DW, Simon J. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 1999;20:5180–202.

34. WHO. WHO | Mental Health Atlas 2005. http://www.who.int/mental_health/evidence/mhAtlas05/en/. Accessed 8 Mar 2016.

35. Nakimuli-Mpunngu E, Bais JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav. 2012;16:201–18.

36. Marconi VC, Wu B, Hampton J, Ordóñez CE, Johnson BA, Singh D, et al. Early warning indicators for first-line virologic failure independent of adherence measures in a South African urban clinic. AIDS Patient Care STDs. 2013;27:657–68.

37. Terasaki DJ, Gelaye B, Berhane Y, Williams MA. Anger expression, violent behavior, and symptoms of depression among male college students in ethiopia. BMC Public Health. 2009;9:13.

38. Wagner JG, Holloway J, Ghosh-Dastidar B, Kityo C, Mugyenyi P. Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in uganda. J Psychosom Res. 2011;70:440–8.

39. Pence BW, Glaye B, Asialli J, O’Donnell JK, Tayong G, Kats D, et al. Validity of an interviewer-administered patient health questionnaire-9 to screen for depression in HIV-infected patients in cameroon. J Affect Disord. 2012;143:208–13.

40. Adewuya AO, Ola BA, Afolabi OO. Validity of the patient health questionnaire (PHQ-9) as a screening tool for depression amongst nigerian university students. J Affect Disord. 2008;689–93.

41. Peltzer K, Naidoo P, Louw J, Mateke G, Zuma K, Mchunu G, et al. Screening and brief interventions for hazardous and harmful alcohol use among patients with active tuberculosis attending primary public care clinics in south africa: Results from a cluster randomized controlled trial. BMC Public Health. 2013;13:699.

42. Pengpid S, Peltzer K, Skal L, Van der Heever H. Screening and brief interventions for hazardous and harmful alcohol use among hospital outpatients in south africa: Results from a randomized controlled trial. BMC Public Health. 2013;13:644.

43. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with C4D count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5:e109.

44. Habeer JE, Kiswanuka J, Nansera D, Muzoora C, Hunt PW, So J, et al. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural uganda. AIDS. 2013;27:2166–8.